Hemophagocytic Lymphohistiocytosis in a Patient with Rheumatoid Arthritis on Pembrolizumab for Lung Adenocarcinoma.


Journal

Internal medicine (Tokyo, Japan)
ISSN: 1349-7235
Titre abrégé: Intern Med
Pays: Japan
ID NLM: 9204241

Informations de publication

Date de publication:
15 Apr 2020
Historique:
pubmed: 6 2 2020
medline: 2 10 2020
entrez: 4 2 2020
Statut: ppublish

Résumé

Immune checkpoint inhibitors have changed the landscape of classic cancer treatment. However, their use is associated with the emergence of new adverse events. An elderly man with rheumatoid arthritis was started on pembrolizumab for newly diagnosed advanced lung cancer. He subsequently developed hemophagocytic lymphohistiocytosis (HLH), which is potentially fatal but has not been properly established as an immune checkpoint inhibition-induced event. We herein report the case of a patient with pembrolizumab-induced HLH.

Identifiants

pubmed: 32009093
doi: 10.2169/internalmedicine.3889-19
pmc: PMC7205536
doi:

Substances chimiques

Antibodies, Monoclonal, Humanized 0
pembrolizumab DPT0O3T46P

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1075-1080

Références

Oncotarget. 2017 Jul 14;8(35):59977-59985
pubmed: 28938698
Lung Cancer. 2018 Nov;125:150-156
pubmed: 30429014
J Rheumatol. 1995 Jun;22(6):1043-7
pubmed: 7674228
Blood. 2011 Nov 24;118(22):5794-8
pubmed: 21881043
N Engl J Med. 2016 Nov 03;375(18):1749-1755
pubmed: 27806233
JAMA Oncol. 2016 Feb;2(2):234-40
pubmed: 26633184
Ann Oncol. 2017 Feb 1;28(2):368-376
pubmed: 27687304
Ann Intern Med. 2018 Jan 16;168(2):121-130
pubmed: 29297009
Blood. 2011 Oct 13;118(15):4041-52
pubmed: 21828139
Blood. 2011 Oct 27;118(17):4577-84
pubmed: 21900192
Ann Oncol. 2017 Jun 1;28(6):1403
pubmed: 28368439
JAMA Oncol. 2018 Mar 1;4(3):374-378
pubmed: 28975219
Nature. 2017 May 25;545(7655):495-499
pubmed: 28514441
Ann Intern Med. 1997 Sep 1;127(5):356-64
pubmed: 9273826
J Immunother Cancer. 2018 Jul 16;6(1):73
pubmed: 30012206
JAMA Oncol. 2018 Dec 1;4(12):1721-1728
pubmed: 30242316
Intern Med. 2019;58(5):699-702
pubmed: 30828042
Clin Ther. 2019 Jan;41(1):59-67
pubmed: 30528047
Front Immunol. 2019 Feb 01;10:119
pubmed: 30774631
Eur Rev Med Pharmacol Sci. 2012 Oct;16(10):1414-24
pubmed: 23104659

Auteurs

Yu Akagi (Y)

Department of Respiratory Medicine, Japanese Red Cross Medical Center, Japan.

Nobuyasu Awano (N)

Department of Respiratory Medicine, Japanese Red Cross Medical Center, Japan.

Minoru Inomata (M)

Department of Respiratory Medicine, Japanese Red Cross Medical Center, Japan.

Naoyuki Kuse (N)

Department of Respiratory Medicine, Japanese Red Cross Medical Center, Japan.

Mari Tone (M)

Department of Respiratory Medicine, Japanese Red Cross Medical Center, Japan.

Hanako Yoshimura (H)

Department of Respiratory Medicine, Japanese Red Cross Medical Center, Japan.

Tatsunori Jo (T)

Department of Respiratory Medicine, Japanese Red Cross Medical Center, Japan.

Kohei Takada (K)

Department of Respiratory Medicine, Japanese Red Cross Medical Center, Japan.

Toshio Kumasaka (T)

Department of Pathology, Japanese Red Cross Medical Center, Japan.

Takehiro Izumo (T)

Department of Respiratory Medicine, Japanese Red Cross Medical Center, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH